Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease ...
Annovis Bio (ANVS) announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries ...
Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's. The company is developing innovative therapies that ...
In recent trading, Annovis Bio Inc (ANVS) stock price has shown some volatility, fluctuating -0.59% over the last five trades and -13.2 ...
Annovis Bio (ANVS) stock slipped after the company said the FDA accepted its updated protocol for a Phase 3 trial for its ...
MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company ...
MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage ...
Shares of Annovis Bio, Inc. (NYSE:ANVS – Get Free Report) have received an average rating of “Buy” from the seven analysts that are covering the company, MarketBeat reports.One equities ...
Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback